Aimmune’s peanut allergy drug hits PhIII targets
A Phase III trial assessing Aimmune Therapeutics’ experimental peanut allergy drug AR101 has hit its primary targets.
Read More
Tag: PALISADE
First UK patient enrolled in peanut allergy trial
Children and adolescents in the UK with peanut allergy are among the first to enrol in a Europe-wide study investigating a new oral immunotherapy for the condition.
Read More
- MHRA approves new treatment for severe alopecia areata
- Aplagon doses first patient in phase 2a trial of APAC
- NHS to offer fezolinetant for menopause‑related hot flushes and night‑sweats
- UCB reports superiority of bimekizumab in psoriatic arthritis study
- Kainova reports positive results for DT‑9081 in advanced solid tumours
